Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FLT3 mutation
i
Other names:
FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2322
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FLT3-ITD mutation (90)
FLT3-TKD mutation (13)
FLT3 D835Y (12)
FLT3 F691L (11)
FLT3 D835 (8)
FLT3 D835V (6)
FLT3-ITD mutation + FLT3-TKD mutation (5)
DNMT3A mutation + FLT3-ITD mutation (4)
FLT3 D698N (4)
FLT3 D835H (4)
FLT3 G697R (4)
FLT3 N676K (4)
FLT3 Y842C (4)
FLT3 mutation + NPM1 mutation (4)
FLT3 N676D (3)
FLT3 N676D + FLT3 Y842C (3)
FLT3 N676T (3)
FLT3 mutation + DNMT3A mutation (3)
FLT3 mutation + NRAS mutation (3)
FLT3 wild-type (3)
FLT3-ITD mutation + FLT3 D835 (3)
FLT3-ITD mutation + MLL rearrangement (3)
FLT3-ITD mutation + NPM1 mutation (3)
FLT3‐ITD + NPM1 mutation (3)
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation (3)
FLT3 D835A (2)
FLT3 D835F (2)
FLT3 D835N (2)
FLT3 I836 (2)
FLT3 Y842H (2)
FLT3 mutation + MLL mutation (2)
FLT3-ITD mutation + FLT3 D835Y (2)
FLT3-ITD mutation + FLT3 F691L (2)
FLT3-ITD mutation + IDH1 mutation (2)
FLT3-ITD mutation + IDH2 mutation (2)
FLT3-ITD mutation + WT1 mutation (2)
FLT3‐ITD (2)
CEBPZ rearrangement + FLT3-TKD mutation (1)
FLT3 840GS (1)
FLT3 A627T (1)
FLT3 D651G (1)
FLT3 D835E (1)
FLT3 D835G (1)
FLT3 D839G (1)
FLT3 E588_Y589INSKYFYVDFRE (1)
FLT3 F691L + FLT3 D835F (1)
FLT3 F691L + FLT3 D835H (1)
FLT3 F691L + FLT3 D835V (1)
FLT3 F691L + FLT3 D835Y (1)
FLT3 F691L + FLT3 D839G (1)
FLT3 F691L + FLT3 Y842C (1)
FLT3 G619C (1)
FLT3 G846S (1)
FLT3 I687F (1)
FLT3 NPOS + FLT3 D835N (1)
FLT3 V592A + FLT3 D835N (1)
FLT3 V592_D593INSDFREY (1)
FLT3 Y591_V592INSVDFREYE (1)
FLT3 mutation + IDH1 mutation (1)
FLT3 mutation + NRAS mutation + PTPN11 mutation (1)
FLT3 mutation + PTPN11 mutation (1)
FLT3 positive (1)
FLT3-ITD F692L + NPM1 mutation (1)
FLT3-ITD mutation + ASXL1 mutation (1)
FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)
FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)
FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)
FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L (1)
FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)
FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)
FLT3‐ITD + DNMT3A mutation (1)
FLT3‐ITD + WT1 mutation (1)
MLL rearrangement + FLT3 mutation (1)
NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation (1)
NPM1 mutation + FLT3-TKD mutation (1)
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)
FLT3 A848P (0)
FLT3 F691I (0)
FLT3 F691L + FLT3 Y842H (0)
FLT3 V592A (0)
FLT3-ITD F692L (0)
FLT3-ITD mutation (90)
FLT3-TKD mutation (13)
FLT3 D835Y (12)
FLT3 F691L (11)
FLT3 D835 (8)
FLT3 D835V (6)
FLT3-ITD mutation + FLT3-TKD mutation (5)
DNMT3A mutation + FLT3-ITD mutation (4)
FLT3 D698N (4)
FLT3 D835H (4)
FLT3 G697R (4)
FLT3 N676K (4)
FLT3 Y842C (4)
FLT3 mutation + NPM1 mutation (4)
FLT3 N676D (3)
FLT3 N676D + FLT3 Y842C (3)
FLT3 N676T (3)
FLT3 mutation + DNMT3A mutation (3)
FLT3 mutation + NRAS mutation (3)
FLT3 wild-type (3)
FLT3-ITD mutation + FLT3 D835 (3)
FLT3-ITD mutation + MLL rearrangement (3)
FLT3-ITD mutation + NPM1 mutation (3)
FLT3‐ITD + NPM1 mutation (3)
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation (3)
FLT3 D835A (2)
FLT3 D835F (2)
FLT3 D835N (2)
FLT3 I836 (2)
FLT3 Y842H (2)
FLT3 mutation + MLL mutation (2)
FLT3-ITD mutation + FLT3 D835Y (2)
FLT3-ITD mutation + FLT3 F691L (2)
FLT3-ITD mutation + IDH1 mutation (2)
FLT3-ITD mutation + IDH2 mutation (2)
FLT3-ITD mutation + WT1 mutation (2)
FLT3‐ITD (2)
CEBPZ rearrangement + FLT3-TKD mutation (1)
FLT3 840GS (1)
FLT3 A627T (1)
FLT3 D651G (1)
FLT3 D835E (1)
FLT3 D835G (1)
FLT3 D839G (1)
FLT3 E588_Y589INSKYFYVDFRE (1)
FLT3 F691L + FLT3 D835F (1)
FLT3 F691L + FLT3 D835H (1)
FLT3 F691L + FLT3 D835V (1)
FLT3 F691L + FLT3 D835Y (1)
FLT3 F691L + FLT3 D839G (1)
FLT3 F691L + FLT3 Y842C (1)
FLT3 G619C (1)
FLT3 G846S (1)
FLT3 I687F (1)
FLT3 NPOS + FLT3 D835N (1)
FLT3 V592A + FLT3 D835N (1)
FLT3 V592_D593INSDFREY (1)
FLT3 Y591_V592INSVDFREYE (1)
FLT3 mutation + IDH1 mutation (1)
FLT3 mutation + NRAS mutation + PTPN11 mutation (1)
FLT3 mutation + PTPN11 mutation (1)
FLT3 positive (1)
FLT3-ITD F692L + NPM1 mutation (1)
FLT3-ITD mutation + ASXL1 mutation (1)
FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)
FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)
FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)
FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L (1)
FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)
FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)
FLT3‐ITD + DNMT3A mutation (1)
FLT3‐ITD + WT1 mutation (1)
MLL rearrangement + FLT3 mutation (1)
NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation (1)
NPM1 mutation + FLT3-TKD mutation (1)
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)
FLT3 A848P (0)
FLT3 F691I (0)
FLT3 F691L + FLT3 Y842H (0)
FLT3 V592A (0)
FLT3-ITD F692L (0)
›
Related tests:
LeukoStrat® CDx FLT3 Mutation Assay (6)
LeukoStrat® CDx FLT3 Mutation Assay (6)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 inhibitor
Sensitive: B - Late Trials
FLT3 inhibitor
Sensitive
:
B
FLT3 inhibitor
Sensitive: B - Late Trials
FLT3 inhibitor
Sensitive
:
B
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
venetoclax + azacitidine
Sensitive: B - Late Trials
venetoclax + azacitidine
Sensitive
:
B
venetoclax + azacitidine
Sensitive: B - Late Trials
venetoclax + azacitidine
Sensitive
:
B
FLT3 mutation
Leukemia
FLT3 mutation
Leukemia
midostaurin
Sensitive: B - Late Trials
midostaurin
Sensitive
:
B
midostaurin
Sensitive: B - Late Trials
midostaurin
Sensitive
:
B
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: B - Late Trials
azacitidine
Sensitive
:
B
azacitidine
Sensitive: B - Late Trials
azacitidine
Sensitive
:
B
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
HM43239
Sensitive: B - Late Trials
HM43239
Sensitive
:
B
HM43239
Sensitive: B - Late Trials
HM43239
Sensitive
:
B
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
quizartinib + RAIN-32
Sensitive: C2 – Inclusion Criteria
quizartinib + RAIN-32
Sensitive
:
C2
quizartinib + RAIN-32
Sensitive: C2 – Inclusion Criteria
quizartinib + RAIN-32
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
sunitinib
Sensitive: C2 – Inclusion Criteria
sunitinib
Sensitive
:
C2
sunitinib
Sensitive: C2 – Inclusion Criteria
sunitinib
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
quizartinib
Sensitive: C2 – Inclusion Criteria
quizartinib
Sensitive
:
C2
quizartinib
Sensitive: C2 – Inclusion Criteria
quizartinib
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
Hypomethylating agent + venetoclax
Sensitive: C2 – Inclusion Criteria
Hypomethylating agent + venetoclax
Sensitive
:
C2
Hypomethylating agent + venetoclax
Sensitive: C2 – Inclusion Criteria
Hypomethylating agent + venetoclax
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
venetoclax + gilteritinib
Sensitive: C2 – Inclusion Criteria
venetoclax + gilteritinib
Sensitive
:
C2
venetoclax + gilteritinib
Sensitive: C2 – Inclusion Criteria
venetoclax + gilteritinib
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
CEP-701
Sensitive: C2 – Inclusion Criteria
CEP-701
Sensitive
:
C2
CEP-701
Sensitive: C2 – Inclusion Criteria
CEP-701
Sensitive
:
C2
FLT3 mutation
Myelodysplastic Syndrome
FLT3 mutation
Myelodysplastic Syndrome
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 inhibitor + gilteritinib
Sensitive: C2 – Inclusion Criteria
FLT3 inhibitor + gilteritinib
Sensitive
:
C2
FLT3 inhibitor + gilteritinib
Sensitive: C2 – Inclusion Criteria
FLT3 inhibitor + gilteritinib
Sensitive
:
C2
FLT3 mutation
Myelodysplastic Syndrome
FLT3 mutation
Myelodysplastic Syndrome
quizartinib
Sensitive: C2 – Inclusion Criteria
quizartinib
Sensitive
:
C2
quizartinib
Sensitive: C2 – Inclusion Criteria
quizartinib
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
FLT3 mutation
Myelodysplastic Syndrome
FLT3 mutation
Myelodysplastic Syndrome
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
ORY-1001
Sensitive: C2 – Inclusion Criteria
ORY-1001
Sensitive
:
C2
ORY-1001
Sensitive: C2 – Inclusion Criteria
ORY-1001
Sensitive
:
C2
FLT3 mutation
Leukemia
FLT3 mutation
Leukemia
venetoclax + gilteritinib
Sensitive: C2 – Inclusion Criteria
venetoclax + gilteritinib
Sensitive
:
C2
venetoclax + gilteritinib
Sensitive: C2 – Inclusion Criteria
venetoclax + gilteritinib
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
GS-9876
Sensitive: C2 – Inclusion Criteria
GS-9876
Sensitive
:
C2
GS-9876
Sensitive: C2 – Inclusion Criteria
GS-9876
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
GS-9973
Sensitive: C2 – Inclusion Criteria
GS-9973
Sensitive
:
C2
GS-9973
Sensitive: C2 – Inclusion Criteria
GS-9973
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
STI-8591
Sensitive: C2 – Inclusion Criteria
STI-8591
Sensitive
:
C2
STI-8591
Sensitive: C2 – Inclusion Criteria
STI-8591
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
cytarabine + midostaurin
Sensitive: C2 – Inclusion Criteria
cytarabine + midostaurin
Sensitive
:
C2
cytarabine + midostaurin
Sensitive: C2 – Inclusion Criteria
cytarabine + midostaurin
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
venetoclax + midostaurin
Sensitive: C3 – Early Trials
venetoclax + midostaurin
Sensitive
:
C3
venetoclax + midostaurin
Sensitive: C3 – Early Trials
venetoclax + midostaurin
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login